Sandoz launches rival version of AbbVie’s arthritis drug Humira

(Reuters) – Swiss drugmaker Sandoz said on Saturday it had launched a biosimilar version of AbbVie Inc’s big selling arthritis treatment Humira, adding to U.S. competition for the drug that started in January. The Novartis-owned company said its drug, Hyrimoz, will be priced at a 5% discount off Humira’s current list price of $6,922 per…

Read More